RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation at three upcoming investor conferences. Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at each conference where he will focus on BDSI’s product pipeline, including BEMA Buprenorphine for pain and opioid dependence, and BEMA Granisetron for the prevention of chemotherapy induced nausea and vomiting.
